Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 688 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 688 shares of the stock in a transaction dated Monday, October 26th. The stock was sold at an average price of $43.19, for a total value of $29,714.72. Following the sale, the insider owned 177,269 shares of the company’s stock, valued at $7,656,248.11. This represents a 0.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Monday, October 12th, Jason Adair sold 7,301 shares of Liquidia stock. The stock was sold at an average price of $28.48, for a total value of $207,932.48.
• On Friday, August 21st, Jason Adair sold 73,631 shares of Liquidia stock. The stock was sold at an average price of $69.09, for a total value of $5,087,165.79.

Liquidia Trading Up 0.6%

Shares of LQDA opened at $45.72 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. Liquidia Corporation has a 1 year low of $22.05 and a 1 year high of $93.61. The company has a 50 day simple moving average of $54.12 and a two-hundred day simple moving average of $54.22. The firm has a market cap of $4.09 billion, a P/E ratio of 33.37, a price-to-earnings-growth ratio of 0.37 and a beta of 0.61.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. During the same period last year, the firm posted ($0.49) EPS. Liquidia’s quarterly revenue was up 1842.1% compared to the same quarter last year. On average, equities analysts expect that Liquidia Corporation will post 2.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Liquidia

A number of hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp purchased a new position in Liquidia during the 2nd quarter valued at $29,694,000. Bank of America Corp DE increased its stake in Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares during the period. Capricorn Fund Managers Ltd purchased a new stake in Liquidia in the first quarter worth $9,337,000. Eversept Partners LP increased its stake in Liquidia by 33.0% in the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after purchasing an additional 167,949 shares during the period. Finally, Seven Fleet Capital Management LP lifted its position in shares of Liquidia by 124.5% during the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock worth $7,732,000 after purchasing an additional 113,609 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

LQDA has been the topic of several research analyst reports. Wall Street Zen cut shares of Liquidia from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Royal Bank Of Canada set a $65.00 price objective on shares of Liquidia in a report on Thursday, October 15th. Weiss Ratings upgraded Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Jefferies Financial Group upgraded Liquidia to a “strong-buy” rating in a research report on Thursday, October 1st. Finally, Raymond James Financial reaffirmed an “outperform” rating on shares of Liquidia in a report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $72.85.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with pulmonary hypertension and other serious cardiopulmonary diseases. The company is headquartered in Research Triangle Park, North Carolina, and uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition for inhaled and injectable medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder formulation of treprostinil delivered through a proprietary inhaler.